source
- Matchpoint Therapeutics raises $150 million Series B to move oral T-cell modulator MPT-062 toward clinical trialsMatchpoint Therapeutics announced the closing of a $150 million Series B financing round. The round was co-led by Nextech Invest and Norwest, with participation from Sanofi Ventures and several exi…
- ARM playbook proposes data reuse to slash gene-editing R&D costs and broaden rare-disease therapiesThe Alliance for Regenerative Medicine released a new playbook that outlines how developers of gene‑editing therapies can reuse existing data to lower research and development expenses. The guidanc…